These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7858909)

  • 1. The role of native apolipoprotein B-containing lipoproteins in atherosclerosis: cellular mechanisms.
    Sehayek E; Eisenberg S
    Curr Opin Lipidol; 1994 Oct; 5(5):350-3. PubMed ID: 7858909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of lipoproteins in atherogenesis. Evolving concepts.
    Getz GS
    Ann N Y Acad Sci; 1990; 598():17-28. PubMed ID: 2248436
    [No Abstract]   [Full Text] [Related]  

  • 3. Atherogenicity of triglyceride-rich lipoproteins.
    Krauss RM
    Am J Cardiol; 1998 Feb; 81(4A):13B-17B. PubMed ID: 9526808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDL, VLDL, chylomicrons and atherosclerosis.
    Nordestgaard BG; Tybjaerg-Hansen A
    Eur J Epidemiol; 1992 May; 8 Suppl 1():92-8. PubMed ID: 1505659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The very low- and intermediate-density lipoprotein fraction isolated from apolipoprotein E-knockout mice transforms macrophages to foam cells through an apolipoprotein E-independent pathway.
    Hakamata H; Sakaguchi H; Zhang C; Sakashita N; Suzuki H; Miyazaki A; Takeya M; Takahashi K; Kitamura N; Horiuchi S
    Biochemistry; 1998 Sep; 37(39):13720-7. PubMed ID: 9753460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the pathogenesis of atherosclerosis.
    Wissler RW
    Am J Med; 1991 Jul; 91(1B):3S-9S. PubMed ID: 1867233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein heterogeneity and apolipoprotein B metabolism.
    Packard CJ; Shepherd J
    Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3542-56. PubMed ID: 9437204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase.
    Lee C; Sigari F; Segrado T; Hörkkö S; Hama S; Subbaiah PV; Miwa M; Navab M; Witztum JL; Reaven PD
    Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1437-46. PubMed ID: 10364074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
    Olofsson SO; Borèn J
    J Intern Med; 2005 Nov; 258(5):395-410. PubMed ID: 16238675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.
    Skålén K; Gustafsson M; Rydberg EK; Hultén LM; Wiklund O; Innerarity TL; Borén J
    Nature; 2002 Jun; 417(6890):750-4. PubMed ID: 12066187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E.
    Weisgraber KH; Innerarity TL; Rall SC; Mahley RW
    Ann N Y Acad Sci; 1990; 598():37-48. PubMed ID: 2248450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of extracellular retention of low density lipoproteins in atherosclerosis.
    Borén J; Gustafsson M; Skålén K; Flood C; Innerarity TL
    Curr Opin Lipidol; 2000 Oct; 11(5):451-6. PubMed ID: 11048887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple changes in apoprotein B containing lipoproteins after ethanol withdrawal in alcoholic men.
    Kervinen K; Savolainen MJ; Kesäniemi YA
    Ann Med; 1991 Oct; 23(4):407-13. PubMed ID: 1930937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
    Véniant MM; Sullivan MA; Kim SK; Ambroziak P; Chu A; Wilson MD; Hellerstein MK; Rudel LL; Walzem RL; Young SG
    J Clin Invest; 2000 Dec; 106(12):1501-10. PubMed ID: 11120757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
    Anber V; Millar JS; McConnell M; Shepherd J; Packard CJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2507-14. PubMed ID: 9409221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.
    Hodis HN; Mack WJ; Dunn M; Liu C; Liu C; Selzer RH; Krauss RM
    Circulation; 1997 Apr; 95(8):2022-6. PubMed ID: 9133510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertriglyceridemia: lipoprotein receptors and atherosclerosis.
    Gianturco SH; Gotto AM; Bradley WA
    Adv Exp Med Biol; 1985; 183():47-71. PubMed ID: 4036704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis.
    Proctor SD; Vine DF; Mamo JC
    Curr Opin Lipidol; 2002 Oct; 13(5):461-70. PubMed ID: 12352009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of atherogenic low density lipoproteins (LDL) in the pathogenesis of atherosclerosis.
    Kita T; Yokode M; Ishii K; Arai H; Nagano Y
    Ann N Y Acad Sci; 1990; 598():188-93. PubMed ID: 2248438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.